Navigation Links
NicOx' Naproxcinod ABPM Data Presented at American Heart Association
Date:11/7/2007

hieve statistical significance for DBP (p=0.007).

Blood pressure data were collected in the first phase 3 trial for naproxcinod (the 301 study) using Office Blood Pressure Measurements (OBPM) up to 13 weeks (see NOTE 2). The top-line results of this trial revealed a sustained reduction in blood pressure for naproxcinod, compared to baseline and naproxen. Additional results from this phase 3 trial are due to be presented on November 10, 2007, at the 71st annual meeting of the American College of Rheumatology.

"This ABPM trial was the first clinical study focusing specifically on naproxcinod's 24-hour blood pressure profile and its results reveal a clear difference compared to naproxen, which is one of the best-known cardiovascular NSAIDs," said Raymond Townsend, Professor of Medicine at the University of Pennsylvania, Philadelphia, who advised NicOx on the ABPM study. "The medical community recognizes the importance of blood pressure control in reducing the rate of serious cardiovascular events in elderly patients. These data add to the promising blood pressure results obtained by OBPM in the first 13-week phase 3 study and, if supported by the results of the ongoing 302 and 303 phase 3 studies, should contribute to naproxcinod becoming a valuable alternative to selective and non-selective NSAIDs for treating the signs and symptoms of osteoarthritis."

The presentation showed naproxcinod was well tolerated during the study. The number of subjects with at least one treatment related adverse event was low and evenly spread between naproxcinod and naproxen. There were no adverse events suggesting clinically significant hypotensive effects in either group.

Details of study design and ABPM monitoring

The trial was an 8-week, double-blind, randomized, cross-over study in which 131 male and female healthy volunteers were enrolled at 15 US clinical sites to receive either naproxcinod 750 mg bid, followed by naproxen 500 mg bid for 2 weeks, or the
'/>"/>

SOURCE NicOx S.A.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
2. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
5. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
8. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
9. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
10. Promising Data from Paratek Pharmaceuticals MAR Inhibitor Program Presented in Late Breaker Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
11. New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
(Date:7/10/2014)... Minn. The benefits of medical imaging far outweigh ... The Right Way, with The Right Radiation Dose. However, ... and Mayo Clinic is leading a collaborative effort to ... commentary, published online in the Journal of Patient ... the Joint Commission, the Intersociety Accreditation Commission, and the ...
(Date:7/10/2014)... at Rutgers University-Newark says the human brain operates much ... finding that could provide a better understanding of schizophrenia, ... afflict an estimated 13.6 million Americans. , In newly ... Cole, an assistant professor at the Center for Molecular ... of a person at rest is basically the same ...
(Date:7/10/2014)... Low-fat cheeses and cakes that are just as ... supermarket shelves, thanks to fresh insights into how ... and texture. , Funded by the Engineering ... at Heriot-Watt University and the University of Edinburgh ... into micro-particles and therefore closely mimic the behaviour ...
(Date:7/9/2014)... Cincinnati, OH, July 10, 2014 -- The World Health ... 60 minutes of moderate to vigorous physical activity (MVPA) ... most of their MVPA during school hours. Therefore, ... school hours would increase MVPA. In a new ... Pediatrics , researchers confirmed that time spent outdoors after ...
(Date:7/9/2014)... at the Perelman School of Medicine at the University ... Institute have received an $8 million grant from the ... photodynamic light therapy (PDT) in patients with malignant pleural ... often manifests itself in the lining of the lungs ... The grant will fund a clinical trial and additional ...
Breaking Medicine News(10 mins):Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:Working to loosen the grip of severe mental illness 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Penn mesothelioma program receives $8 million NCI grant 2
... Calif., April 16 Edwards Lifesciences,Corporation (NYSE: ... and technologies to,treat advanced cardiovascular disease, announced today ... company,s board of directors, effective May,31, 2008., ... LLC, has been a director,of Edwards since 2000, ...
... Wireless, the,builder and operator of the nation,s most ... mobile phone applications, today,announced the availability of The ... provides Verizon Wireless customers with detailed drug,information and ... (Photo: http://www.newscom.com/cgi-bin/prnh/20080416/NYW008 ), The ...
... FRANCISCO, April 15 The Medical Tourism,Association, the ... tourism industry, announces the World Medical Tourism &,Global ... the,first medical tourism convention to take place in ... 9-12th, 2008 at the Westin St.,Francis in San ...
... owns your medical tests results and your personal health ... of personal liberty and freedom of information. Now, researchers ... Management have introduced the notion of ownership of medical ... adoption of personal health records. , Personal health records ...
... Most Promising ... of Technology, SUNNYVALE, Calif., April 16 Agito Networks, ... that it has been named a finalist for the Red ... based in North America., The Red Herring editorial board ...
... Publications LLC today,announced that its highly anticipated book ... will be released on April 28, 2008 in ... online book retailers,including Amazon.com., *(PHOTO 72dpi: ... Creating Your Dream Life.) An entirely new ...
Cached Medicine News:Health News:Edwards Lifesciences Announces Retirement of Director Vernon Loucks 2Health News:Verizon Wireless Customers Can Now Get Medication Information and Dosing Reminders with the Pill Phone Application on Their Phones 2Health News:Verizon Wireless Customers Can Now Get Medication Information and Dosing Reminders with the Pill Phone Application on Their Phones 3Health News:Medical Tourism Association Announces World's Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008 2Health News:Medical Tourism Association Announces World's Largest Medical Tourism Convention in San Francisco, CA USA - September 9-12, 2008 3Health News:Breaking personal health records 2Health News:Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies 2Health News:Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies 3Health News:Agito Networks Named Finalist for Red Herring North America 100 Award out of More Than 800 Companies 4Health News:21 Days to Creating Your Dream Life Will be Unleashed on April 28, 2008 2
... Flexible Cystoscope System using EndoSheath Technology ... for urologists in both their hospitals ... CST-2000 flexible cystoscope with the sterile, ... cystoscopy procedures, while minimizing the costs ...
... Super-Sect is a single-use device that ... minimal thermal spread and vapor sealing ... It can be used for resection ... tumor. It is also an excellent ...
... Cryocare® CS is a ... and treatment system designed ... allow unlimited flexibility. Cryocare ... meet specific physician needs ...
... Oncura's SeedNet system is a minimally invasive ... to learn and simple to use, SeedNet ... the cryoablation process. SeedNet is the ... Ultra-thin needles, exclusive to the SeedNet system, ...
Medicine Products: